{"nctId":"NCT01773967","briefTitle":"Impact of Emergency Department Probiotic (LGG) Treatment of Pediatric Gastroenteritis","startDateStruct":{"date":"2014-07","type":"ACTUAL"},"conditions":["Gastroenteritis"],"count":971,"armGroups":[{"label":"LGG","type":"EXPERIMENTAL","interventionNames":["Drug: LGG"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: micro-crystalline cellulose"]}],"interventions":[{"name":"LGG","otherNames":["Lactobacillus GG ATCC 53103","Lactobacillus rhamnosus","culturelle"]},{"name":"micro-crystalline cellulose","otherNames":["placebo micro-crystalline cellulose"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Age 3-48 months (have not yet reached their fourth birthday); AND\n2. Presence of 3 or more watery stools within 24 hours of screening; AND\n3. Duration of vomiting or diarrhea less than 7 days; AND\n4. Symptoms consistent with acute intestinal infectious process.\n\nExclusion Criteria:\n\n1. Presence of an indwelling vascular access line; OR\n2. Presence of structural heart disease excluding non-pathological heart murmurs; OR\n3. Receiving immunosuppressive therapy or history of immunodeficiency; OR\n4. Hematochezia in the preceding 48 hours; OR\n5. Chronic gastrointestinal problems (e.g. short gut syndrome, inflammatory bowel disease); OR\n6. Patients with known pancreatitis; OR\n7. History of abdominal surgery; OR\n8. Critically ill patients; OR\n9. Family member with an indwelling vascular access line, or on immunosuppressive therapy, or with a known immunodeficiency; OR\n10. Bilious emesis; OR\n11. Probiotic use (supplement) in the preceding 2 weeks; OR\n12. Oral or intravenous steroid use in the preceding six months; OR\n13. Previously enrolled in this trial; OR\n14. Allergy to lactobacillus or Microcrystalline Cellulose (MCC); OR\n15. Allergy to erythromycin, clindamycin, AND betalactam antibiotics (all); OR\n16. Not available for daily follow-up while symptomatic; OR\n17. Parent/guardian not speaking English or Spanish; OR\n18. Under 6 months old AND premature (\\<37 weeks).","healthyVolunteers":false,"sex":"ALL","minimumAge":"3 Months","maximumAge":"48 Months","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Modified Vesikari Scale Score >=9","description":"This is a validated gastroenteritis severity score that includes duration and frequency of diarrhea, duration and frequency of vomiting, duration and frequency of fever and use of health care resources. Scores \\>=9 indicate moderate-severe gastroenteritis. Higher is worse.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"55","spread":null},{"groupId":"OG001","value":"60","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With LGG Bacteremia","description":"bacteremia caused by LGG","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Diarrhea Duration","description":"diarrhea duration in hours after randomization","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"49.7","spread":null},{"groupId":"OG001","value":"50.9","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":8,"n":483},"commonTop":["other","other"]}}}